Virios Therapeutics (NASDAQ:VIRI) and Xencor (NASDAQ:XNCR) Review

Virios Therapeutics ( NASDAQ:VIRI – Get Your Free Report ) and Xencor ( NASDAQ:XNCR – Get Your Free Report ) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.

return

This table compares Virios Therapeutics and Xencor’s net margins, return on equity and return on assets.

Volatility and risk

Virios Therapeutics has a beta of 1.61, indicating that its stock price is 61% more volatile than the S&P 500. Comparatively, Xencor has a beta of 0.69, indicating that its stock price is 31% less volatile than the S&P 500.

Insider and institutional ownership

9.1% of Virios Therapeutics shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are held by insiders. Comparatively, 5.2% of Xencor shares are held by insiders. Strong institutional ownership is an indication that big money managers, endowments and hedge funds believe a company is poised for long-term growth.

Rating and Earnings

This table compares Virios Therapeutics and Xencor’s revenue, earnings per share (EPS) and valuation.

Virios Therapeutics has higher revenue, but lower revenue than Xencor. Xencor is trading at a lower price-to-earnings ratio than Virios Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst recommendations

This is a summary of current ratings and recommendations for Virios Therapeutics and Xencor as reported by MarketBeat.

Virios Therapeutics currently has a consensus target price of $0.60, indicating a potential upside of 185.04%. Xencor has a consensus target price of $34.44, indicating a potential upside of 94.93%. Given Virios Therapeutics’ higher possible upside, research analysts plainly believe Virios Therapeutics is more favorable than Xencor.

Summary

Virios Therapeutics beats Xencor in 8 of the 14 factors compared between the two stocks.

About Virios Therapeutics

(Get a free report)

Virios Therapeutics, Inc., an early-stage biotechnology company, is focused on developing novel antiviral therapies to treat diseases associated with an abnormal virally triggered immune response. The company’s lead development candidate is IMC-1, a fixed-dose combination of famciclovir and celecoxib for the treatment of fibromyalgia. It is also developing IMC-2, a combination of valacyclovir and celecoxib for the treatment of fatigue, sleep, attention, pain, autonomic function and anxiety associated with prolonged COVID. The company was formerly known as Innovative Med Concepts, LLC and has changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

About Xencor

(Get a free report)

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies and cytokine therapies to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab which targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It is developing Plamotamab, a bispecific antibody, which is in phase I clinical trials to treat non-Hodgkin’s lymphoma; Vudalimab, a bispecific antibody, is in a phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer and other types of solid tumors. The company is also developing XmAb306, which is in phase I clinical trials for the treatment of solid tumors; XmAb104, which is in phase II clinical trial to treat patients with selected solid tumors; XmAb564 which is in phase Ia clinical trial for the treatment of autoimmune diseases; AMG 509, which is in phase I clinical trial for the treatment of prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in phase I clinical trial to treat patients with solid tumors. In addition, the company is developing VIR-3434, which is in phase II clinical study for patients with hepatitis B virus infection; and VIR-2482 which is in Phase 2 clinical trial for the treatment of hepatitis B virus. The Company is developing AIMab7195 to reduce serum levels of IgE that mediate allergic responses and allergic diseases; Obexelimab to treat autoimmune diseases; and Xpro1595 to treat patients with Alzheimer’s disease and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was founded in 1997 and is headquartered in Pasadena, California.

Get Virios Therapeutics news and reviews daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Virios Therapeutics and related companies with MarketBeat.com ‘s FREE daily email newsletter.